X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary

British Journal of Cancer

Volumn 110, Issue 12, 2014, Pages 2881-2886

  Miyamoto, M ^a   Takano, M ^a   Iwaya, K ^a   Shinomiya, N ^a   Kato, M ^a   Aoyama, T ^a   Sasaki, N ^a   Goto, T ^a   Suzuki, A ^a   Hitrata, J ^a   Furuya, K ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Chemoresistance; Clear cell adenocarcinoma; Ovarian cancer; Platinum; X chromosome linked inhibitor of apoptosis (XIAP)

Indexed keywords

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DISEASE-FREE SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84902554025     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.255     Document Type: Article

References (30)

1. Aird KM, Ghanayem RB, Peplinski S, Lyerly HK, Devi GR (2010) X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. Mol Cancer Ther 9: 1432-1442
2. Appleman LJ (2011) MET signaling pathway: A rational target for cancer therapy. J Clin Oncol 29: 4837-4838
3. Asselin E, Mills GB, Tsang BK (2001) XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 61: 1862-1868. (Pubitemid 32692000
4. Bu R, Uddin S, Bavi P, Hussain AR, Al-Dayel F, Ghourab S, Ahmed M, Al-Kuraya KS (2011) HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. Lab Invest 91: 124-137
5. Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L, Cooper K (2006) Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma. J Surg Oncol 93: 379-386
6. Jiang C, Yi XP, Shen H, Li YX (2012) Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion. World J Gastroenterol 18: 2956-2965
7. Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M, Brown D, Mor G (2003) Phenoxodiol-An isoflavone analog-induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 22: 2611-2620. (Pubitemid 36605609
8. Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, Berghuis B, Daugherty J, Grabinski T, Toro J, Giambernardi T, Skinner RS, Gross M, Hudson E, Kort E, Lengyel E, Ventura A, West RA, Xie Q, Hay R, Woude GV, Cao B (2009) A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol 17: 57-67
9. Lacasse EC, Baird S, Korneluk RG, MacKenzie AE (1998) The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17: 3247-3259. (Pubitemid 29043977
10. Li J, Feng Q, Kim JM, Schneiderman D, Liston P, Li M, Vanderhyden B, Faught W, Fung MF, Senterman M, Korneluk RG, Tsang BK (2001) Human ovarian cancer and cisplatin resistance: Possible role of inhibitor of apoptosis proteins. Endocrinology 142: 370-380. (Pubitemid 32183698
11. Ma JJ, Chen BL, Xin XY (2009) XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 146: 222-226
12. Mizutani Y, Nakanishi H, Li YN, Matsubara H, Yamamoto K, Sato N, Shiraishi T, Nakamura T, Mikami K, Okihara K, Takaha N, Ukimura O, Kawauchi A, Nonomura N, Bonavida B, Miki T (2007) Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol 30: 919-925
13. Sasa H, Ishii K, Hirata J, Kikuchi Y, Nagata I, Kawai T, Senoo A, Sugita M, Sugishita T, Tenjin Y (1993) Establishment and characterization of a CA-125-producing human ovarian clear cell carcinoma cell line. Hum Cell 6: 279-286
14. Sasaki H, Sheng Y, Kotsuji F, Tsang BK (2000) Downregulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 60: 5659-5666
15. Schimmer AD, Dalili S, Batey RA, Riedl SJ (2006) Targeting XIAP for the treatment of malignancy. Cell Death Differ 13: 179-188. (Pubitemid 43102202
16. Serov SF, Scully RE, Sobin LH (1973) International histologic classification of tumors. In No.9. Histologic Typing of Ovarian Tumors. World Health Organization: Geneva
17. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K (2000) Clinical characteristics of clear cell carcinoma of the ovary. Cancer 88: 2584-2587
18. Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Sugiyama T (2006) Clear cell carcinoma of the ovary: A retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94: 1369-1374. (Pubitemid 43772268
19. Takano M, Sugiyama T, Yaegashi N, Sakuma M, Suzuki M, Saga Y, Kuzuya K, Kigawa J, Shimada M, Tsuda H, Moriya T, Yoshizaki A, Kita T, Kikuchi Y (2008) Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: A retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer 18: 937-942
20. Takano M, Tsuda H, Sugiyama T (2012) Clear cell carcinoma of the ovary: Is there a role of histology-specific treatment?. J Exp Clin Cancer Res 31: 53
21. Takano M, Goto T, Kato M, Sasaki N, Miyamoto M, Furuya K (2013) Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary. Int J Clin Oncol 18: 556-557
22. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, Andreeff M, Reed JC (2000) Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 6: 1796-1803. (Pubitemid 30305074
23. Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F, Karawajew L, Ludwig WD, Wuchter C (2004a) High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood De novo acute myeloid leukemia. Clin Cancer Res 10: 3737-3744. (Pubitemid 38697607
24. Tamm I, Richter S, Scholz F, Schmelz K, Oltersdorf D, Karawajew L, Schoch C, Haferlach T, Ludwig WD, Wuchter C (2004b) XIAP expression correlates with monocytic differentiation in adult De novo AML: Impact on prognosis. Hematol J 5: 489-495. (Pubitemid 40045282
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
26. Van Themsche C, Leblanc V, Parent S, Asselin E (2009) X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization. J Biol Chem 284: 20462-20466
27. Winter 3rd WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP. Gynecologic Oncology Group Study (2007) Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25: 3621-3627
28. Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O (2011) Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: Their roles in tumor progression and prognostication of the patient. Mod Pathol 24: 1146-1155
29. Yang L, Cao Z, Yan H, Wood WC (2003) Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: Implication for cancer specific therapy. Cancer Res 63: 6815-6824. (Pubitemid 37322964
30. Yang XH, Feng ZE, Yan M, Hanada S, Zuo H, Yang CZ, Han ZG, Guo W, Chen WT, Zhang P (2012) XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer. PLoS One 7: E31601.